MedPath

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Phase 3
Terminated
Conditions
Breast Cancer
Interventions
Registration Number
NCT00543127
Lead Sponsor
Spanish Breast Cancer Research Group
Brief Summary

Postmenopausal women with hormone receptor positive and negative Her2 tumours.

Before randomization, the patients will be stratified according to the center, positive nodes (0 vs. 1-3 vs. ≥4), previous chemotherapy (yes vs no) and hormonal receptors status.

Detailed Description

It is expected that disease-free survival for patients receiving Anastrozole alone for 5 years will be up to 90%. An increase of 3% in disease-free survival (DFS) is expected in the arm of Fulvestrant plus Anastrozole, i.e a DFS of up to 93%. They will be required 1358 patients per treatment group (i.e, 2716 patients in total) to give 80% power, alfa bilateral 0.05, and OR 0.6888. Assuming 5% screening failures 2852 patients are required to enter the study. In Jun-2010 the recruitment was stopped due to lack of support of the financier based on the result of Faslodex® and Arimidex® in Combination Trial (FACT-trial), comparing Fulvestrant + Anastrozole vs Anastrozole alone in 1st relapse showed no difference in time to progression at more than 40 months follow-up.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
870
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Fulvestrant + AnastrozoleFulvestrantFulvestrant loading dose regimen will consist of two 5 ml intramuscular injections on day 0 (500 mg), 250 mg single injection on days 14 and 28, and 250 mg single injection every 28 days thereafter for 3 years plus Anastrozole 1 mg PO once daily for 5 years
Fulvestrant + AnastrozoleAnastrozoleFulvestrant loading dose regimen will consist of two 5 ml intramuscular injections on day 0 (500 mg), 250 mg single injection on days 14 and 28, and 250 mg single injection every 28 days thereafter for 3 years plus Anastrozole 1 mg PO once daily for 5 years
AnastrozoleAnastrozoleAnastrozole 1 mg will be administered orally as one tablet daily for 5 years.
Primary Outcome Measures
NameTimeMethod
Disease Free Survival (DFS) EventsUp to 5 years

Disease-free survival (DFS) has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.

DFS event is defined as the evidence of local and/or distant recurrence, new primary breast tumour, or death from any cause.

Secondary Outcome Measures
NameTimeMethod
Breast Cancer Specific Survival (BCsS) EventsUp to 5 years

BCsS events has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to BCsS in patients treated with anastrozole for 5 years.

BCsS event is defined as the death from breast cancer.

Time to Recurrence (TR) EventUp to 5 years

TR event has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.

TR event is defined as the evidence of breast cancer recurrence (local and/or distant recurrence of breast cancer, does not include second primary malignancies or deaths from any cause).

Overall Survival (OS) EventUp to 5 years

OS event has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.

OS event is defined as the death from any cause.

Trial Locations

Locations (53)

Hospital de Sagunto

🇪🇸

Sagunto, Valencia, Spain

Hospital Lluís Alcanyis

🇪🇸

Xátiva, Valencia, Spain

Hospital Universitario Fundación Alcorcón

🇪🇸

Alcorcón, Madrid, Spain

Hospital Universitario de Canarias

🇪🇸

La Laguna, Santa CRUZ DE Tenerife, Spain

Hospital Municipal de Badalona

🇪🇸

Badalona, Barcelona, Spain

Hospital Usp San Jaime

🇪🇸

Torrevieja, Alicante, Spain

Hospital General Universitario de Elda

🇪🇸

Elda, Alicante, Spain

Hospital General de Granollers

🇪🇸

Granollers, Barcelona, Spain

Hospital San Agustín de Avilés

🇪🇸

Avilés, Asturias, Spain

Hospital General Universitario de Elche

🇪🇸

Elche, Alicante, Spain

Hospital de Torrevieja Salud Ute

🇪🇸

Torrevieja, Alicante, Spain

Hospital Universitario Virgen de Los Lirios

🇪🇸

Alcoy, Alicante, Spain

Corporació Sanitaria Parc Taulí

🇪🇸

Sabadell, Barcelona, Spain

Hospital Universitari Germans Trias I Pujol

🇪🇸

Badalona, Barcelona, Spain

Hospital Mutua de Terrassa

🇪🇸

Terrassa, Barcelona, Spain

Hospital de Barbastro

🇪🇸

Barbastro, Huesca, Spain

Institut Catalá D'Oncología L'Hospitalet

🇪🇸

L'hospitalet de Llobregat, Barcelona, Spain

Hospital Universitario Marqués de Valdecilla

🇪🇸

Santander, Cantabria, Spain

Consorci Sanitari de Terrassa

🇪🇸

Terrassa, Barcelona, Spain

Consorcio Hospitalario Provincial de Castellón

🇪🇸

Castellón de La Plana, Castellón, Spain

Complejo Hospitalario Universitario Insular-Materno Infantil

🇪🇸

Las Palmas de Gran Canaria, LAS Palmas, Spain

Hospital de Basurto

🇪🇸

Bilbao, Vizcaya, Spain

Hospital de La Santa Creu I Sant Pau

🇪🇸

Barcelona, Spain

Hospital Donostia

🇪🇸

Donostia-san Sebastián, Guipúzcoa, Spain

Onkologikoa

🇪🇸

Donostia-san Sebastián, Guipúzcoa, Spain

Hospital Universitario de Valme

🇪🇸

Dos Hermanas, Sevilla, Spain

Centro Oncológico de Galicia

🇪🇸

A Coruña, Spain

Complejo Hospitalario Universitario A Coruña

🇪🇸

A Coruña, Spain

Hospital Clinic I Provincial de Barcelona

🇪🇸

Barcelona, Spain

Complejo Hospitalario Torrecárdenas

🇪🇸

Almería, Spain

Hospital Universitario Puerta Del Mar

🇪🇸

Cadiz, Spain

HOSPITAL UNIVERSITARI DE GIRONA DR. JOSEP TRUETA (ICO de Girona)

🇪🇸

Girona, Spain

Hospital Universitario Reina Sofía

🇪🇸

Córdoba, Spain

Hospital Universitario San Cecilio

🇪🇸

Granada, Spain

Hospital General Universitario de Guadalajara

🇪🇸

Guadalajara, Spain

Hospital Juan Ramón Jiménez

🇪🇸

Huelva, Spain

Complejo Hospitalario de Jaén

🇪🇸

Jaén, Spain

Hospital Universitario Arnau de Vilanova de Lleida

🇪🇸

Lleida, Spain

Hospital General Universitario Gregorio Marañón

🇪🇸

Madrid, Spain

CENTRO INTEGRAL ONCOLÓGICO CLARA CAMPAL (Hospital Madrid Norte Sanchinarro)

🇪🇸

Madrid, Spain

Hospital Universitario Ramón Y Cajal

🇪🇸

Madrid, Spain

Hospital Clínico Universitario San Carlos

🇪🇸

Madrid, Spain

Hospital General Universitario Morales Meseguer

🇪🇸

Murcia, Spain

Hospital Clínico Universitario Virgen de La Victoria

🇪🇸

Malaga, Spain

Hospital Regional Universitario Carlos Haya

🇪🇸

Malaga, Spain

Hospital Universitario Nuestra Señora de Candelaria

🇪🇸

Santa Cruz de Tenerife, Spain

Hospital Universitario Virgen Del Rocío

🇪🇸

Sevilla, Spain

Instituto Valenciano de Oncología

🇪🇸

Valencia, Spain

Hospital Virgen de La Salud

🇪🇸

Toledo, Spain

Consorcio Hospital General Universitario de Valencia

🇪🇸

Valencia, Spain

Hospital Clínico Universitario de Valencia

🇪🇸

Valencia, Spain

Hospital Universitario Arnau de Vilanova de Valencia

🇪🇸

Valencia, Spain

Hospital Universitario Miguel Servet

🇪🇸

Zaragoza, Spain

© Copyright 2025. All Rights Reserved by MedPath